A Comprehensive Computational Study of the Interaction between Human Serum Albumin and Fullerenes

Journal of Physical Chemistry B

Volumn 119, Issue 48, 2015, Pages 14971-14985

  Leonis, Georgios ^a   Avramopoulos, Aggelos ^a   Papavasileiou, Konstantinos D ^a   Reis, Heribert ^a   Steinbrecher, Thomas ^b   Papadopoulos, Manthos G ^a  

^a INSTITUTE OF BIOLOGY   (Greece)

^b KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING SITES; BINS; BODY FLUIDS; CHARGE TRANSFER; FATTY ACIDS; FREE ENERGY; FULLERENES; HYDROGEN BONDS; MOLECULAR ORBITALS; PHOTODYNAMIC THERAPY; QUANTUM THEORY; VAN DER WAALS FORCES;

ALLOSTERIC MODULATION; BIOLOGICAL APPLICATIONS; COMPUTATIONAL STUDIES; DISPERSION ENERGIES; ENERGY DECOMPOSITION ANALYSIS; FRAGMENT MOLECULAR ORBITAL; HUMAN SERUM ALBUMINS; THEORETICAL APPROACH;

BINDING ENERGY;

FULLERENE DERIVATIVE; SERUM ALBUMIN;

CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; HYDROGEN BOND; MOLECULAR DYNAMICS; QUANTUM THEORY;

FULLERENES; HUMANS; HYDROGEN BONDING; MOLECULAR DYNAMICS SIMULATION; MOLECULAR STRUCTURE; QUANTUM THEORY; SERUM ALBUMIN;

EID: 84948784170     PISSN: 15206106     EISSN: 15205207     Source Type: Journal    
DOI: 10.1021/acs.jpcb.5b05998     Document Type: Article

References (97)

1. Mu, Q.; Jiang, G.; Chen, L.; Zhou, H.; Fourches, D.; Tropsha, A.; Yan, B. Chemical basis of interactions between engineered nanoparticles and biological systems Chem. Rev. 2014, 114, 7740-7781 10.1021/cr400295a
2. Karmali, P. P.; Simberg, D. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems Expert Opin. Drug Delivery 2011, 8, 343-357 10.1517/17425247.2011.554818
3. Lewinski, N.; Colvin, V.; Drezek, R. Cytotoxicity of nanoparticles Small 2008, 4, 26-49 10.1002/smll.200700595
4. Cedervall, T.; Lynch, I.; Lindman, S.; Berggard, T.; Thulin, E.; Nilsson, H.; Dawson, K. A.; Linse, S. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 2050-2055 10.1073/pnas.0608582104
5. Sharifi, S.; Behzadi, S.; Laurent, S.; Forrest, M. L.; Stroeve, P.; Mahmoudi, M. Toxicity of nanomaterials Chem. Soc. Rev. 2012, 41, 2323-2343 10.1039/C1CS15188F
6. Nienhaus, G. U.; Maffre, P.; Nienhaus, K. Studying the protein corona on nanoparticles by FCS Methods Enzymol. 2013, 519, 115-137 10.1016/B978-0-12-405539-1.00004-X
7. Bamrungsap, S.; Zhao, Z. L.; Chen, T.; Wang, L.; Li, C. M.; Fu, T.; Tan, W. H. Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system Nanomedicine 2012, 7, 1253-1271 10.2217/nnm.12.87
8. Calvaresi, M.; Zerbetto, F. Fullerene sorting proteins Nanoscale 2011, 3, 2873-2881 10.1039/c1nr10082c
9. Calvaresi, M.; Zerbetto, F. Baiting proteins with C-60 ACS Nano 2010, 4, 2283-2299 10.1021/nn901809b
10. Innocenti, A.; Durdagi, S.; Doostdar, N.; Strom, T. A.; Barron, A. R.; Supuran, C. T. Nanoscale enzyme inhibitors: fullerenes inhibit carbonic anhydrase by occluding the active site entrance Bioorg. Med. Chem. 2010, 18, 2822-2828 10.1016/j.bmc.2010.03.026
11. Durdagi, S.; Supuran, C. T.; Strom, T. A.; Doostdar, N.; Kumar, M. K.; Barron, A. R.; Mavromoustakos, T.; Papadopoulos, M. G. In silico drug screening approach for the design of magic bullets: a successful example with anti-HIV fullerene derivatized amino acids J. Chem. Inf. Model. 2009, 49, 1139-1143 10.1021/ci900047s
12. Thakral, S.; Thakral, N. K. Potential Medical Applications of Fullerenes: An Overview. In Bio-Nanotechnology; Wiley-Blackwell: Chichester, U.K., 2013; pp 424-441.
13. Cui, Q.; Yang, X.; Ebrahimi, A.; Li, J. Fullerene-biomolecule conjugates and their biomedicinal applications Int. J. Nanomed. 2013, 9, 77-92 10.2147/IJN.S52829
14. Sapsford, K. E.; Algar, W. R.; Berti, L.; Gemmill, K. B.; Casey, B. J.; Oh, E.; Stewart, M. H.; Medintz, I. L. Functionalizing nanoparticles with biological molecules: Developing chemistries that facilitate nanotechnology Chem. Rev. 2013, 113, 1904-2074 10.1021/cr300143v
15. Bakry, R.; Vallant, R. M.; Najam-Ul-Haq, M.; Rainer, M.; Szabo, Z.; Huck, C. W.; Bonn, G. K. Medicinal applications of fullerenes Int. J. Nanomed. 2007, 2, 639-649
16. Bosi, S.; Da Ros, T.; Spalluto, G.; Balzarini, J.; Prato, M. Synthesis and anti-HIV properties of new water-soluble bis-functionalized[60]fullerene derivatives Bioorg. Med. Chem. Lett. 2003, 13, 4437-4440 10.1016/j.bmcl.2003.09.016
17. Huy, P. D. Q.; Li, M. S. Binding of fullerenes to amyloid beta fibrils: size matters Phys. Chem. Chem. Phys. 2014, 16, 20030-20040 10.1039/C4CP02348J
18. Nicholson, J. P.; Wolmarans, M. R.; Park, G. R. The role of albumin in critical illness Brit J. Anaesth 2000, 85, 599-610 10.1093/bja/85.4.599
19. Kratz, F. A clinical update of using albumin as a drug vehicle-A commentary J. Controlled Release 2014, 190, 331-336 10.1016/j.jconrel.2014.03.013
20. Yang, F.; Zhang, Y.; Liang, H. Interactive association of drugs binding to human serum albumin Int. J. Mol. Sci. 2014, 15, 3580-3595 10.3390/ijms15033580
21. Fasano, M.; Curry, S.; Terreno, E.; Galliano, M.; Fanali, G.; Narciso, P.; Notari, S.; Ascenzi, P. The extraordinary ligand binding properties of human serum albumin IUBMB Life 2005, 57, 787-796 10.1080/15216540500404093
22. Zhang, X.-f.; Shu, C.-y.; Xie, L.; Wang, C.-r.; Zhang, Y.-z.; Xiang, J.-f.; Li, L.; Tang, Y.-l. Protein conformation changes induced by a novel organophosphate-containing water-soluble derivative of a C60 fullerene nanoparticle J. Phys. Chem. C 2007, 111, 14327-14333 10.1021/jp073267u
23. He, X. M.; Carter, D. C. Atomic-structure and chemistry of human serum-albumin Nature 1992, 358, 209-215 10.1038/358209a0
24. Artali, R.; Bombieri, G.; Calabi, L.; Del Pra, A. A molecular dynamics study of human serum albumin binding sites Farmaco 2005, 60, 485-495 10.1016/j.farmac.2005.04.010
25. Qu, X.; Komatsu, T.; Sato, T.; Glatter, O.; Horinouchi, H.; Kobayashi, K.; Tsuchida, E. Structure, photophysical property, and cytotoxicity of human serum albumin complexed with tris(dicarboxymethylene)[60]fullerene Bioconjugate Chem. 2008, 19, 1556-1560 10.1021/bc800207j
26. Zhang, M. F.; Xu, Z. Q.; Ge, Y. S.; Jiang, F. L.; Liu, Y. Binding of fullerol to human serum albumin: spectroscopic and electrochemical approach J. Photochem. Photobiol., B 2012, 108, 34-43 10.1016/j.jphotobiol.2011.12.006
27. Zhen, M.; Zheng, J.; Ye, L.; Li, S.; Jin, C.; Li, K.; Qiu, D.; Han, H.; Shu, C.; Yang, Y. et al. Maximizing the relaxivity of Gd-complex by synergistic effect of HSA and carboxylfullerene ACS Appl. Mater. Interfaces 2012, 4, 3724-3729 10.1021/am300817z
28. Abdulmalik, A.; Hibah, A.; Zainy, B. M.; Makoto, A.; Daisuke, I.; Masaki, O.; Kaneto, U.; Fumitoshi, H. Preparation of soluble stable C60/human serum albumin nanoparticles via cyclodextrin complexation and their reactive oxygen production characteristics Life Sci. 2013, 93, 277-282 10.1016/j.lfs.2013.06.021
29. Song, M.; Liu, S.; Yin, J.; Wang, H. Interaction of human serum album and C(60) aggregates in solution Int. J. Mol. Sci. 2011, 12, 4964-4974 10.3390/ijms12084964
30. Li, S.; Zhao, X. C.; Mo, Y. M.; Cummings, P. T.; Heller, W. T. Human serum albumin interactions with C-60 fullerene studied by spectroscopy, small-angle neutron scattering, and molecular dynamics simulations J. Nanopart. Res. 2013, 15, 1769 10.1007/s11051-013-1769-0
31. Rozhkov, S. P.; Goryunov, A. S.; Sukhanova, G. A.; Borisova, A. G.; Rozhkova, N. N.; Andrievsky, G. V. Protein interaction with hydrated C60 fullerene in aqueous solutions Biochem. Biophys. Res. Commun. 2003, 303, 562-566 10.1016/S0006-291X(03)00392-9
32. Belgorodsky, B.; Fadeev, L.; Ittah, V.; Benyamini, H.; Zelner, S.; Huppert, D.; Kotlyar, A. B.; Gozin, M. Formation and characterization of stable human serum albumin-tris-malonic acid [C-60]fullerene complex Bioconjugate Chem. 2005, 16, 1058-1062 10.1021/bc050103c
33. Benyamini, H.; Shulman-Peleg, A.; Wolfson, H. J.; Belgorodsky, B.; Fadeev, L.; Gozin, M. Interaction of C-60-fullerene and carboxyfullerene with proteins: Docking and binding site alignment Bioconjugate Chem. 2006, 17, 378-386 10.1021/bc050299g
34. Sudlow, G.; Birkett, D. J.; Wade, D. N. The characterization of two specific drug binding sites on human serum albumin Mol. Pharmacol. 1975, 11, 824-832
35. Vallant, R. M.; Szabo, Z.; Trojer, L.; Najam-ul-Haq, M.; Rainer, M.; Huck, C. W.; Bakry, R.; Bonn, G. K. A new analytical material-enhanced laser desorption ionization (MELDI) based approach for the determination of low-mass serum constituents using fullerene derivatives for selective enrichment J. Proteome Res. 2007, 6, 44-53 10.1021/pr060347m
36. Kayat, J.; Gajbhiye, V.; Tekade, R. K.; Jain, N. K. Pulmonary toxicity of carbon nanotubes: a systematic report Nanomedicine 2011, 7, 40-49 10.1016/j.nano.2010.06.008
37. Bobylev, A. G.; Kornev, A. B.; Bobyleva, L. G.; Shpagina, M. D.; Fadeeva, I. S.; Fadeev, R. S.; Deryabin, D. G.; Balzarini, J.; Troshin, P. A.; Podlubnaya, Z. A. Fullerenolates: metallated polyhydroxylated fullerenes with potent anti-amyloid activity Org. Biomol. Chem. 2011, 9, 5714-5719 10.1039/c1ob05067b
38. Piette, J. Mutagenic and genotoxic properties of singlet oxygen J. Photochem. Photobiol., B 1990, 4, 335-339 10.1016/1011-1344(90)85039-Y
39. Komatsu, T.; Nakagawa, A.; Qu, X. Structural and mutagenic approach to create human serum albumin-based oxygen carrier and photosensitizer Drug Metab. Pharmacokinet. 2009, 24, 287-299 10.2133/dmpk.24.287
40. Graves, A. P.; Shivakumar, D. M.; Boyce, S. E.; Jacobson, M. P.; Case, D. A.; Shoichet, B. K. Rescoring docking hit lists for model cavity sites: predictions and experimental testing J. Mol. Biol. 2008, 377, 914-934 10.1016/j.jmb.2008.01.049
41. Wang, J.; Wang, W.; Kollman, P. A.; Case, D. A. Automatic atom type and bond type perception in molecular mechanical calculations J. Mol. Graphics Modell. 2006, 25, 247-260 10.1016/j.jmgm.2005.12.005
42. Case, D. A.; Darden, T. A.; Cheatham, T. E.; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Walker, R. C.; Zhang, W.; Merz, K. M. AMBER 12; University of California: San Francisco, 2012.
43. Salomon-Ferrer, R.; Case, D. A.; Walker, R. C. An overview of the Amber biomolecular simulation package Wiley Interdiscip. Rev.: Comput. Mol. Sci. 2013, 3, 198-210 10.1002/wcms.1121
44. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and testing of a general amber force field J. Comput. Chem. 2004, 25, 1157-1174 10.1002/jcc.20035
45. Hornak, V.; Abel, R.; Okur, A.; Strockbine, B.; Roitberg, A.; Simmerling, C. Comparison of multiple Amber force fields and development of improved protein backbone parameters Proteins: Struct., Funct., Genet. 2006, 65, 712-725 10.1002/prot.21123
46. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulationg liquid water J. Chem. Phys. 1983, 79, 926-935 10.1063/1.445869
47. Izaguirre, J. A.; Catarello, D. P.; Wozniak, J. M.; Skeel, R. D. Langevin stabilization of molecular dynamics J. Chem. Phys. 2001, 114, 2090-2098 10.1063/1.1332996
48. Salomon-Ferrer, R.; Götz, A. W.; Poole, D.; Le Grand, S.; Walker, R. C. Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh Ewald J. Chem. Theory Comput. 2013, 9, 3878-3888 10.1021/ct400314y
49. Götz, A. W.; Williamson, M. J.; Xu, D.; Poole, D.; Le Grand, S.; Walker, R. C. Routine microsecond molecular dynamics simulations with AMBER on GPUs. 1. Generalized Born J. Chem. Theory Comput. 2012, 8, 1542-1555 10.1021/ct200909j
50. Le Grand, S.; Götz, A. W.; Walker, R. C. SPFP: Speed without compromise¯A mixed precision model for GPU accelerated molecular dynamics simulations Comput. Phys. Commun. 2013, 184, 374-380 10.1016/j.cpc.2012.09.022
51. Ryckaert, J. P.; Ciccotti, G.; Berendsen, H. J. C. Numerical integration of the Cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes J. Comput. Phys. 1977, 23, 327-341 10.1016/0021-9991(77)90098-5
52. Daura, X.; Gademann, K.; Jaun, B.; Seebach, D.; van Gunsteren, W. F.; Mark, A. E. Peptide folding: When simulation meets experiment Angew. Chem., Int. Ed. 1999, 38, 236-240 10.1002/(SICI)1521-3773(19990115)38:1/2<236::AID-ANIE236>3.3.CO;2-D
53. Hess, B.; Kutzner, C.; van der Spoel, D.; Lindahl, E. GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation J. Chem. Theory Comput. 2008, 4, 435-447 10.1021/ct700301q
54. Hayward, S.; Berendsen, H. J. Systematic analysis of domain motions in proteins from conformational change: new results on citrate synthase and T4 lysozyme Proteins: Struct., Funct., Genet. 1998, 30, 144-154 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N
55. Kollman, P. A.; Massova, I.; Reyes, C.; Kuhn, B.; Huo, S.; Chong, L.; Lee, M.; Lee, T.; Duan, Y.; Wang, W. et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models Acc. Chem. Res. 2000, 33, 889-897 10.1021/ar000033j
56. Gohlke, H.; Kiel, C.; Case, D. A. Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes J. Mol. Biol. 2003, 330, 891-913 10.1016/S0022-2836(03)00610-7
57. Leonis, G.; Steinbrecher, T.; Papadopoulos, M. G. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study J. Chem. Inf. Model. 2013, 53, 2141-2153 10.1021/ci4002102
58. Hou, T.; Wang, J.; Li, Y.; Wang, W. Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations J. Chem. Inf. Model. 2011, 51, 69-82 10.1021/ci100275a
59. Cao, R.; Huang, N.; Wang, Y. Evaluation and application of MD-PB/SA in structure-based hierarchical virtual screening J. Chem. Inf. Model. 2014, 54, 1987-1996 10.1021/ci5003203
60. Uciechowska, U.; Schemies, J.; Neugebauer, R. C.; Huda, E. M.; Schmitt, M. L.; Meier, R.; Verdin, E.; Jung, M.; Sippl, W. Thiobarbiturates as sirtuin inhibitors: virtual screening, free-energy calculations, and biological testing ChemMedChem 2008, 3, 1965-1976 10.1002/cmdc.200800104
61. Kumar, A.; Ito, A.; Hirohama, M.; Yoshida, M.; Zhang, K. Y. Identification of sumoylation activating enzyme 1 inhibitors by structure-based virtual screening J. Chem. Inf. Model. 2013, 53, 809-820 10.1021/ci300618e
62. Chen, Y.; Fang, L.; Peng, S.; Liao, H.; Lehmann, J.; Zhang, Y. Discovery of a novel acetylcholinesterase inhibitor by structure-based virtual screening techniques Bioorg. Med. Chem. Lett. 2012, 22, 3181-3187 10.1016/j.bmcl.2012.03.046
63. Venken, T.; Krnavek, D.; Munch, J.; Kirchhoff, F.; Henklein, P.; De Maeyer, M.; Voet, A. An optimized MM/PBSA virtual screening approach applied to an HIV-1 gp41 fusion peptide inhibitor Proteins: Struct., Funct., Genet. 2011, 79, 3221-3235 10.1002/prot.23158
64. Ferrari, A. M.; Degliesposti, G.; Sgobba, M.; Rastelli, G. Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors Bioorg. Med. Chem. 2007, 15, 7865-7877 10.1016/j.bmc.2007.08.019
65. Tzoupis, H.; Leonis, G.; Avramopoulos, A.; Reis, H.; Czyznikowska, Z.; Zerva, S.; Vergadou, N.; Peristeras, L. D.; Papavasileiou, K. D. et al. Alexis, et al., Elucidation of the binding mechanism of renin using a wide array of computational techniques and biological assays J. Mol. Graphics Modell. 2015, 62, 138-149 10.1016/j.jmgm.2015.09.015
66. Kitaura, K.; Morokuma, K. New energy decomposition scheme for molecular-interactions within Hartree-Fock approximation Int. J. Quantum Chem. 1976, 10, 325-340 10.1002/qua.560100211
67. Morokuma, K. Molecular Orbital Studies of Hydrogen Bonds. III. C⋯-O···H-O hydrogen bond in H2CO···H2O and H2CO···2H2O J. Chem. Phys. 1971, 55, 1236-1244 10.1063/1.1676210
68. Fedorov, D.; Kitaura, K. The Fragment Molecular Orbital Method: Practical Applications to Large Molecular Systems; CRC Press: Boca Raton, FL, 2009.
69. Fedorov, D. G.; Kitaura, K. Pair interaction energy decomposition analysis J. Comput. Chem. 2007, 28, 222-237 10.1002/jcc.20496
70. Schmidt, M. W.; Baldridge, K. K.; Boatz, J. A.; Elbert, S. T.; Gordon, M. S.; Jensen, J. H.; Koseki, S.; Matsunaga, N.; Nguyen, K. A.; Su, S. J. et al. General atomic and molecular electronic-structure system J. Comput. Chem. 1993, 14, 1347-1363 10.1002/jcc.540141112
71. Su, P.; Li, H. Energy decomposition analysis of covalent bonds and intermolecular interactions J. Chem. Phys. 2009, 131, 014102 10.1063/1.3159673
72. Boys, S. F.; Bernardi, F. Calculation of small molecular interactions by differences of separate total energies-Some procedures with reduced errors Mol. Phys. 1970, 19, 553-566 10.1080/00268977000101561
73. Bader, R. F. W. Atoms in Molecules: A Quantum Theory; Clarendon: Oxford, U.K., 1990.
74. Espinosa, E.; Molins, E.; Lecomte, C. Hydrogen bond strengths revealed by topological analyses of experimentally observed electron densities Chem. Phys. Lett. 1998, 285, 170-173 10.1016/S0009-2614(98)00036-0
75. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; et al., Gaussian 09, Revision A; Gaussian, Inc.: Wallingford, CT, 2009.
76. Biegler-Konig, F.; Schonbohm, J. Update of the AIM2000-program for atoms in molecules J. Comput. Chem. 2002, 23, 1489-1494 10.1002/jcc.10085
77. Leonis, G.; Avramopoulos, A.; Salmas, R. E.; Durdagi, S.; Yurtsever, M.; Papadopoulos, M. G. Elucidation of conformational states, dynamics, and mechanism of binding in human kappa-opioid receptor complexes J. Chem. Inf. Model. 2014, 54, 2294-2308 10.1021/ci5002873
78. Vrontaki, E.; Leonis, G.; Avramopoulos, A.; Papadopoulos, M. G.; Simcic, M.; Grdadolnik, S. G.; Afantitis, A.; Melagraki, G.; Hadjikakou, S. K.; Mavromoustakos, T. Stability and binding effects of silver(I) complexes at lipoxygenase-1 J. Enzyme Inhib. Med. Chem. 2015, 30, 539-549 10.3109/14756366.2014.951348
79. Fanali, G.; Rampoldi, V.; Masi, A. d.; Bolli, A.; Lopiano, L.; Ascenzi, P.; Fasano, M. Binding of anti-Parkinson¯s disease drugs to human serum albumin is allosterically modulated IUBMB Life 2010, 62, 371-376 10.1002/iub.317
80. Guizado, T. R. Analysis of the structure and dynamics of human serum albumin J. Mol. Model. 2014, 20, 2450 10.1007/s00894-014-2450-y
81. Curry, S.; Mandelkow, H.; Brick, P.; Franks, N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites Nat. Struct. Biol. 1998, 5, 827-835 10.1038/1869
82. Sugio, S.; Kashima, A.; Mochizuki, S.; Noda, M.; Kobayashi, K. Crystal structure of human serum albumin at 2.5 A resolution Protein Eng., Des. Sel. 1999, 12, 439-446 10.1093/protein/12.6.439
83. Petitpas, I.; Grune, T.; Bhattacharya, A. A.; Curry, S. Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids J. Mol. Biol. 2001, 314, 955-960 10.1006/jmbi.2000.5208
84. Colmenarejo, G. In silico prediction of drug-binding strengths to human serum albumin Med. Res. Rev. 2003, 23, 275-301 10.1002/med.10039
85. Fujiwara, S.-i.; Amisaki, T. Molecular dynamics study of conformational changes in human serum albumin by binding of fatty acids Proteins: Struct., Funct., Genet. 2006, 64, 730-739 10.1002/prot.21053
86. Paris, G.; Ramseyer, C.; Enescu, M. A principal component analysis of the dynamics of subdomains and binding sites in human serum albumin Biopolymers 2014, 101, 561-572 10.1002/bip.22418
87. Leonis, G.; Czyznikowska, Z.; Megariotis, G.; Reis, H.; Papadopoulos, M. G. Computational studies of darunavir into HIV-1 protease and DMPC bilayer: necessary conditions for effective binding and the role of the flaps J. Chem. Inf. Model. 2012, 52, 1542-58 10.1021/ci300014z
88. Tzoupis, H.; Leonis, G.; Durdagi, S.; Mouchlis, V.; Mavromoustakos, T.; Papadopoulos, M. G. Binding of novel fullerene inhibitors to HIV-1 protease: insight through molecular dynamics and molecular mechanics Poisson-Boltzmann surface area calculations J. Comput.-Aided Mol. Des. 2011, 25, 959-976 10.1007/s10822-011-9475-4
89. Tzoupis, H.; Leonis, G.; Megariotis, G.; Supuran, C. T.; Mavromoustakos, T.; Papadopoulos, M. G. Dual inhibitors for aspartic proteases HIV-1 PR and renin: advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations J. Med. Chem. 2012, 55, 5784-5796 10.1021/jm300180r
90. Politi, A.; Leonis, G.; Tzoupis, H.; Ntountaniotis, D.; Papadopoulos, M. G.; Grdadolnik, S. G.; Mavromoustakos, T. Conformational properties and energetic analysis of aliskiren in solution and receptor site Mol. Inf. 2011, 30, 973-985 10.1002/minf.201100077
91. Petitpas, I.; Bhattacharya, A. A.; Twine, S.; East, M.; Curry, S. Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I J. Biol. Chem. 2001, 276, 22804-22809 10.1074/jbc.M100575200
92. Ascenzi, P.; Bocedi, A.; Notari, S.; Fanali, G.; Fesce, R.; Fasano, M. Allosteric modulation of drug binding to human serum albumin Mini-Rev. Med. Chem. 2006, 6, 483-489 10.2174/138955706776361448
93. Ascenzi, P.; Fasano, M. Allostery in a monomeric protein: The case of human serum albumin Biophys. Chem. 2010, 148, 16-22 10.1016/j.bpc.2010.03.001
94. Fanali, G.; Rampoldi, V.; di Masi, A.; Bolli, A.; Lopiano, L.; Ascenzi, P.; Fasano, M. Binding of anti-Parkinson¯s disease drugs to human serum albumin is allosterically modulated IUBMB Life 2010, 62, 371-376 10.1002/iub.317
95. Peters, T., Jr. 3-Ligand Binding by Albumin. In All about Albumin; Peters, T., Ed.; Academic Press: San Diego, 1995; pp 76-132.
96. Wanwimolruk, S.; Birkett, D. J.; Brooks, P. M. Structural requirements for drug binding to site II on human serum albumin Mol. Pharmacol. 1983, 24, 458-463
97. Kragh-Hansen, U. Molecular aspects of ligand binding to serum albumin Pharmacol. Rev. 1981, 33, 17-53